GH Stock: Cowen Maintains Buy Rating on Guardant Health

Cowen & Co. maintained its Buy rating on Guardant Health (GH) on May 21, 2026, reaffirming confidence in the precision oncology company. The analyst action follows FDA approval of the G360 Liquid test, a key milestone for the company’s liquid biopsy portfolio. GH stock trades at $118.01, up 2.47% on the news. This maintained rating reflects analyst conviction in Guardant’s growth trajectory and competitive positioning in cancer diagnostics.

Cowen Maintains Buy Rating on Guardant Health Stock

Cowen & Co. held its Buy rating on GH, signaling continued confidence in the company’s strategic direction. The analyst action came after FDA approval of the G360 Liquid test, expanding Guardant’s liquid biopsy offerings for advanced cancer patients. Cowen reiterated its Buy stance based on the regulatory win and market opportunity.

The maintained rating reflects analyst belief that Guardant’s test portfolio strengthens its competitive moat. G360 Liquid joins existing products like Guardant360 CDx and GuardantOMNI in the company’s arsenal. This diversification supports revenue growth and positions GH for sustained market share gains in precision oncology diagnostics.

GH Stock Price Action and Technical Momentum

Guardant Health stock jumped $3.04 to $118.01 following the analyst action and FDA approval news. The 2.47% gain reflects positive market sentiment toward the company’s regulatory progress. Stock trades above its 50-day average of $89.87 and 200-day average of $86.96, signaling strong upward momentum.

Technical indicators show overbought conditions with RSI at 77.38 and MFI at 85.00, suggesting potential pullback risk. However, the stock remains well above its 52-week low of $36.36, demonstrating recovery strength. Volume surged to 4.93 million shares, nearly 2.5x the average, confirming institutional interest in the rating maintenance.

Guardant Health Financial Metrics and Analyst Consensus

GH carries a market cap of $15.6 billion with 132.6 million shares outstanding. The company trades at a 14.43x price-to-sales ratio, reflecting premium valuation typical of high-growth diagnostics firms. Revenue per share stands at $8.23, though the company remains unprofitable with -$3.40 EPS.

Analyst consensus strongly favors GH, with 33 Buy ratings and only 1 Hold among tracked analysts. Meyka AI rates GH with a grade of B+, reflecting strong sector positioning and growth potential. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors. The overwhelming bullish sentiment supports Cowen’s maintained Buy rating.

Guardant Health Growth Trajectory and Future Outlook

Guardant reported 32.9% revenue growth in fiscal 2025, demonstrating strong market demand for liquid biopsy testing. Gross profit surged 40.9%, showing operational leverage as the company scales. The company’s R&D spending of 33.9% of revenue reflects commitment to innovation and pipeline expansion.

Meyka AI’s GH stock forecast projects yearly price targets of $132.91, with five-year estimates reaching $320.66. These forecasts assume continued adoption of Guardant’s test portfolio and market expansion. The G360 Liquid approval removes regulatory uncertainty and validates the company’s technology platform for broader clinical use.

Final Thoughts

Cowen’s maintained Buy rating on Guardant Health reflects confidence in the company’s precision oncology strategy and regulatory progress. The G360 Liquid FDA approval validates GH’s liquid biopsy platform and supports long-term growth. With 33 analyst Buy ratings, strong revenue growth of 32.9%, and a B+ Meyka grade, Guardant Health remains a favored play in cancer diagnostics. Investors should monitor technical overbought conditions while recognizing the company’s strong fundamental momentum and market positioning.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.